Genmab — November 2019
-
Køberne er insisterende til morgen.
-
A: With respect to combining our CD38 antibodies isatuximab with PD-1 or PD-L1, the hypothesis we're testing there is that CD38 plays an important role in the tumor micro environment contributing to an immunosuppressive state and therefore could be a essentially an immuno-oncology opportunity beyond my the role of CD38 as a direct target in myeloma.
-
Now, the tumor microenvironment of every kind of cancer is different. Really quite unique depending on the type of malignancy and that's why we laid out a broad-based program around eight different types of malignancies to test that hypothesis in a number of context.
-
The first couple of indications prostate and lung have not confirmed the hypothesis. But we still feel there's merit to continue that work in the other indications. Several of them are hematologic malignancies, for example, where the tumor microenvironment is very different than solid tumors. And so we'll see those studies to their end. They're small signal seeking studies to test the hypothesis.
-
We've said from the beginning, it's a low probability of success, but we feel that the data -- the preclinical data from our own labs and from the medical community merits that we test the hypothesis in a lean way that would help to determine whether there is a broader opportunity for CD38 antibodies like isatuximab that have unique properties due to the epitope that we target relative to other competitors.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind